MCAS Resource Hub
Mast cell activation syndrome rarely shows up alone, and rarely gets diagnosed quickly. Below is the reading order I would give to anyone newly trying to make sense of MCAS — patient or clinician — plus the external resources I actually rely on.
What this hub is
MCAS is the immune-system half of a constellation that, for many of us, also includes hypermobile Ehlers-Danlos syndrome, POTS, and dysautonomia. Stabilizing one without the others rarely holds. The reading order below reflects that — start with the integrated guide that treats the cluster as a cluster, then move to the more specific protocols, and end with the inflammaging context that helps explain why some patients respond to certain therapies and others don't.
This isn't medical advice. It is field-tested across a decade of treatment, paired with primary literature where it exists.
Read in this order
-
Step 1 · February 15, 2025
Managing hEDS and MCAS, Step by Step
A decade of trial and error compressed into a working protocol — diagnostics, injury sequencing, mast cell control, hormones, and the specific physicians who actually understand the overlap.
-
Step 2 · February 10, 2025
From Disability to Strength: A Decade Inside hEDS, MCAS, and Regenerative Medicine
The personal case study underneath every other post on this site — what hEDS and MCAS did to my body, what surgeries and regenerative work undid, and the specific genetic and biochemical levers that mattered.
-
Step 3 · April 26, 2025
Lessons from Seven Years Inside hEDS, MCAS, POTS, and Dysautonomia
After seven years of trial, error, and rebuilding, these are the interventions that moved me from bedbound to functional: stellate ganglion blocks, environmental detox, slow tendon loading, osteopathic care paired with regenerative medicine, and a multi-year timeline.
-
Step 4 · April 28, 2025
Two Resets: Stellate Ganglion Blocks and the Hoffman Process
Two upstream resets — Neuro-Reset with bilateral stellate blocks and vagus hydrodissection, and the Hoffman Process — that finally made the regenerative work stick after years of cycling back into flares.
-
Step 5 · July 27, 2025
Inflammaging, Longevity, and the Unknowns of Exosome Therapy: A Cautionary View
Inflammaging is a driver of age-related disease, not just a symptom. Exosomes may help, but in a largely unregulated market the variability between batches — even from the same source tissue — makes caution non-optional.
External resources I actually use
- The Mast Cell Disease Society (TMS) — MCAS overview — the canonical patient-facing reference. Start here if MCAS is new to you.
- American Academy of Allergy, Asthma & Immunology — the U.S. specialty society. Their MCAS guidance documents are useful for clinician conversations.
- Dr. Tania Dempsey — one of the leading clinicians treating MCAS in the United States. Her protocols inform much of what is in the integrated guide.
- Dr. Lawrence Afrin — author of the foundational Never Bet Against Occam and the leading clinical reference on MCAS. His framework is the one most other clinicians have built on. He practices at the AIM Center alongside Dr. Tania Dempsey.
- Functional Medicine SF — the integrative side of MCAS care, where the histamine-load, food, and environmental triggers get worked.
- BioReset Medical (Dr. Matthew Cook) — neuro-reset, ketamine, vagal hydrodissection. Named in the stellate ganglion / Hoffman post.
- Extension Health (Dr. Jonathann Kuo) — the NeuroReset program, plasmapheresis, EBOO. Where much of my own dysautonomia work happened.
Lab work I track
Not a complete panel — these are the ones I have found most actionable in my own care, with the caveat that biomarker interpretation in MCAS is hard and patient-specific:
- MMP9 — matrix metalloproteinase 9. Reflects active collagen breakdown during MCAS flares. The single biomarker I check most.
- Tryptase — the classical mast-cell marker. Often normal in MCAS (vs. mastocytosis), but the trend matters.
- Histamine (24-hour urine) — load assessment.
- Prostaglandin D2 (24-hour urine) — under-tested in standard workups; can be informative when histamine is normal.
- N-methylhistamine — histamine metabolite, sometimes catches what plasma histamine misses.
- CRP, IL-6, TNF-α — inflammation panel, also relevant to the inflammaging literature.
If you only read one
Read the step-by-step guide to managing hEDS and MCAS. It treats MCAS in the context where it usually appears — alongside connective tissue fragility and dysautonomia — and gives the specific protocol scaffolding most patient-facing resources skip.
Common questions about MCAS
- What is mast cell activation syndrome (MCAS)?
MCAS is a condition in which mast cells — immune cells found throughout the body — release excessive inflammatory mediators (histamine, tryptase, prostaglandins, MMP9) inappropriately and repeatedly. The result is multi-system symptoms: flushing, hives, GI distress, brain fog, anaphylaxis-like episodes, and reactions to foods, smells, temperature, or stress. The Mast Cell Disease Society is the canonical starting reference.
- What are the symptoms of an MCAS flare?
Flares vary by person but commonly include flushing, itching or hives, GI cramping and nausea, lightheadedness or tachycardia (overlapping with POTS), brain fog, and heightened reactivity to ordinary triggers. The mast cell acts like a conductor of the immune system's orchestra — when it's overactive, many systems play at once.
- What lab tests are used to evaluate MCAS?
The ones I find most actionable: MMP9 (collagen breakdown during flares), tryptase (often normal in MCAS vs. mastocytosis — the trend matters), 24-hour urine histamine and prostaglandin D2, N-methylhistamine, and an inflammation panel (CRP, IL-6, TNF-α). Biomarker interpretation in MCAS is genuinely hard and patient-specific — this is what I track, not a diagnostic protocol.
- What is the first-line approach to controlling MCAS?
Most clinicians start with baseline mast-cell stabilization: a non-sedating H1 blocker plus an H2 blocker, adjusted over weeks, often adding a stabilizer like ketotifen or cromolyn, plus rigorous trigger identification and avoidance. During acute flares, IV protocols (diphenhydramine, famotidine, vitamin C) are used. This is a clinician-directed process — see the integrated guide for how it sequences. Not medical advice.
- How is MCAS connected to hEDS and POTS?
For many patients they form one constellation: hypermobile connective tissue (hEDS) creates chronic micro-injury, MCAS adds inflammatory mediators, and histamine-driven vascular changes worsen dysautonomia and POTS. Stabilizing one without the others rarely holds. The EDS hub covers the connective-tissue half.
- Can exosomes or stem cells help MCAS?
It's an open question. There is mechanistic interest in mast-cell modulation, but exosomes and most stem-cell therapies are not FDA-approved and the MCAS-specific evidence is thin. I take a cautious view — see Inflammaging and the unknowns of exosome therapy for why.